Generic Inrebic Availability
Last updated on May 7, 2025.
Inrebic is a brand name of fedratinib, approved by the FDA in the following formulation(s):
INREBIC (fedratinib hydrochloride - capsule;oral)
-
Manufacturer: BRISTOL-MYERS
Approval date: August 16, 2019
Strength(s): EQ 100MG BASE [RLD]
Is there a generic version of Inrebic available?
No. There is currently no therapeutically equivalent version of Inrebic available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Inrebic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions and methods for treating myelofibrosis
Patent 10,391,094
Issued: August 27, 2019
Inventor(s): Jayan Arvind & Cacace Janice
Assignee(s): Impact Biomedicines, Inc.Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof.
Patent expiration dates:
- June 4, 2032✓✓
- June 4, 2032
-
Methods of treating myeloproliferative disorders
Patent 11,400,092
Issued: August 2, 2022
Inventor(s): Berry; Tymara et al.
Assignee(s): Impact Biomedicines, Inc. (Summit, NJ)The present disclosure provides methods of mitigating thiamine deficiency.
Patent expiration dates:
- September 24, 2039✓
- September 24, 2039
-
Bi-aryl meta-pyrimidine inhibitors of kinases
Patent 7,528,143
Issued: May 5, 2009
Inventor(s): Noronha; Glenn et al.
Assignee(s): TargeGen, Inc. (San Diego, CA)The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases. ##STR00001##
Patent expiration dates:
- November 16, 2031✓✓
- November 16, 2031
-
Bi-aryl meta-pyrimidine inhibitors of kinases
Patent 7,825,246
Issued: November 2, 2010
Inventor(s): Noronha; Glenn et al.
Assignee(s): TargeGen, Inc. (San Diego, CA)The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases. ##STR00001##
Patent expiration dates:
- December 16, 2026✓
- December 16, 2026
-
Use of bi-aryl meta-pyrimidine inhibitors of kinases
Patent 8,138,199
Issued: March 20, 2012
Inventor(s): Noronha Glenn & Hood John D. & Soll Richard M.
Assignee(s): TargeGen, Inc.The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
Patent expiration dates:
- June 30, 2028✓
- June 30, 2028
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 16, 2026 - INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF)
More about Inrebic (fedratinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
